Introduction
============

*Mycobacterium tuberculosis*, the causative agent of tuberculosis, is characterized by a complex cell wall that contributes to its pathogenesis and inherent resistance to therapeutics. The cell wall encompasses multiple layers exterior to the cytosolic membrane and comprises not only peptidoglycan but also arabinogalactan polysaccharide layers and an extremely hydrophobic bilayer known as the mycobacterial outer membrane. Abundant *M. tuberculosis*-specific surface lipids such as sulfatides, acyltrehaloses, and dimycocerosates are noncovalently assembled in the mycobacterial outer membrane and have been implicated in virulence and host immune responses ([@B1]--[@B4]). Sulfolipid-1 (SL-1),[^6^](#FN7){ref-type="fn"} the most abundant sulfatide, is unique to pathogenic mycobacteria (see [Fig. 1](#F1){ref-type="fig"}). The levels of this tetraacylated glycolipid have been positively correlated with strain virulence, but despite a half-century of research into this connection, the biological functions of SL-1 have remained elusive.

Various studies have implicated SL-1 in the inhibition of mitochondrial oxidative phosphorylation, alteration of phagosome-lysosome fusion, and stimulation as well as suppression of cytokine and reactive oxygen species production in host leukocytes ([@B5]--[@B12]). However, *M. tuberculosis* gene disruption strains lacking fully elaborated SL-1 do not appear to have consistent phenotypes or phenotypes distinguishable from wild-type *M. tuberculosis* in animal models of infection ([@B13]--[@B17]). In contrast, the diacyl sulfolipid SL~1278~, a biosynthetic precursor of SL-1, is a well documented active metabolite (see [Fig. 1](#F1){ref-type="fig"}). SL~1278~ was found to bind to the MHC-like lipid receptor CD1b and to stimulate the cytokines IFN-γ and IL-2 in CD8^+^ T-cells from donors positive for the tuberculin skin test ([@B18]). Subsequent work using synthetic analogs of SL~1278~ showed that the ability of SL~1278~ to elicit a CD1-restricted T-cell response is dependent on the length of the fatty acid acyl chains, as well as the presence and number of methyl-branched substituents on the acyl chains ([@B19]).

Elucidating the biosynthetic pathway of SL-1 is a key aspect in understanding how *M. tuberculosis* regulates SL-1 and its precursors as a potential mechanism for host immune modulation. Many of the initial steps in SL-1 biosynthesis have been defined; in addition, SL-1 biosynthesis appears to be coupled to lipid transport across the cytosolic membrane ([@B15]--[@B25]). However, the machinery underlying the final biosynthetic steps is still not understood. The complete elucidation of SL-1 biosynthesis could provide additional avenues for targeted disruption of *M. tuberculosis* sulfolipids and a further means of dissecting their biological roles.

SL-1 comprises a trehalose-2-sulfate (T2S) core elaborated with four acyl groups: a straight-chain fatty acid (palmitate or stearate) and three multiply methyl-branched (hydroxy)phthioceranoic acids (see [Fig. 1](#F1){ref-type="fig"}). The sulfotransferase Stf0 initiates SL-1 biosynthesis by sulfating the abundant disaccharide trehalose to form T2S. The acyltransferase PapA2 then catalyzes the esterification of T2S at the 2′-position to generate a monoacylated intermediate, SL~659~ ([@B15]). The polyketide synthase Pks2 synthesizes methyl-branched (hydroxy)phthioceranoyl chains using an activated fatty acid starter unit provided by the fatty acid AMP ligase FadD23 (also known as FAAL23) ([@B20], [@B21]). PapA1 transfers the product of Pks2 to the 3′-position of SL~659~, yielding diacylated SL~1278~ ([@B15]). Additional acylations at the 6- and 6′-positions of SL~1278~ are required to produce fully elaborated SL-1. These final steps are chemically similar to the reaction catalyzed by PapA1, but there is no *in vitro* evidence that PapA1 is capable of this activity.

Intriguingly, the lipid transporter MmpL8 has been implicated in SL-1 formation. MmpL8 belongs to the RND ([r]{.ul}esistance-[n]{.ul}odulation-[d]{.ul}ivision) permease protein family and is hypothesized to transport SL-1 or SL~1278~ from the cytosolic leaflet to the periplasmic leaflet of the cytosolic membrane ([@B18], [@B19]). The *M. tuberculosis* Δ*mmpL8* gene disruption mutant accumulates the diacyl precursor SL~1278~ in the cell membrane rather than the predicted SL-1, implying that MmpL8 is required for biosynthesis as well as transport ([@B18], [@B19]). However, no member of the RND permease family has been shown to have enzymatic activity, nor does MmpL8 contain any known conserved catalytic domains ([@B22]).

In addition to the genes described above, the SL-1 biosynthetic locus encompasses a putative operon with two ORFs, *rv3821* and *rv3822*, both of which are annotated as conserved hypothetical proteins that we have named Sap and Chp1, respectively ([Fig. 1](#F1){ref-type="fig"}). In this work, we demonstrate that the final steps in SL-1 biosynthesis and SL-1 transport require Sap and Chp1 in addition to MmpL8. Lipid analysis of *M. tuberculosis* gene disruption strains revealed that Sap, Chp1, and MmpL8 are all necessary for *M. tuberculosis* to produce wild-type levels of SL-1. Chp1 and MmpL8 are essential for SL-1 biosynthesis, whereas Sap and MmpL8 are required for sulfolipid transport. *In vitro*, Chp1 was specifically modified by an activity-based fluorophosphonate probe, identifying Chp1 as a serine hydrolase superfamily member. Chp1 can also use a fully synthetic diacyl sulfolipid analog as both an acyl donor and acceptor in two successive, regioselective reactions to form a tetraacylated sulfolipid. Using the combined activities of Chp1, PapA1, and PapA2, all four sulfolipid acylation reactions were reconstituted in a one-pot synthesis. Finally, in *M. tuberculosis*, the clinically approved lipase inhibitor tetrahydrolipstatin (THL) inhibited the activity of Chp1, but not that of PapA1 or PapA2. These data complete the SL-1 biosynthetic pathway and corroborate a model in which SL-1 biosynthesis and transmembrane transport are coupled through the activity of multiple proteins at the membrane-cytosol interface.

![**Genes of unknown function in SL-1 locus may be involved in biosynthesis.** Genes associated with SL-1 biosynthesis are clustered in the *M. tuberculosis* genome, but one putative operon contains two genes of unknown function, *sap* (*rv3821*) and *chp1* (*rv3822*). After sulfation of trehalose (*Tre*) by Stf0, T2S is successively esterified by PapA2 and PapA1. MmpL8 participates in the final two esterifications by an unknown mechanism and is essential for sulfolipid transport; Chp1 and Sap may also be involved.](zbc0091297490001){#F1}

EXPERIMENTAL PROCEDURES
=======================

### 

#### Reagents and Chemicals

T2S and the SL-1 model compound 6,6′-di-*O*-(2-methylarachidoyl)-3′-*O*-(2-methylstearoyl)-2′-*O*-palmitoyltrehalose-2-*O*-sulfate (SL-A) were synthesized as described ([@B23], [@B24]). The synthesis and characterization of 2-*O*-palmitoyl-3-*O*-stearoyl-α,α-[d]{.smallcaps}-trehalose-2′-*O*-sulfate (T2S-PS) and the construction of Chp1 heterologous expression vectors are detailed under [supplemental "Experimental Procedures."](http://www.jbc.org/cgi/content/full/M111.315473/DC1)

#### Bacterial Strains and Growth Media

The *M. tuberculosis* Erdman strain (ATCC 35801) and *Mycobacterium smegmatis* mc^2^155 (ATCC 700084) were grown at 37 °C. The growth medium was 7H9 (liquid) or 7H11 (solid) with 0.5% glycerol and 0.05% Tween 80 plus 0.5% glucose or 10% albumin/dextrose/catalase for *M. smegmatis* and plus 10% oleate/albumin/dextrose/catalase for *M. tuberculosis*. For selective media, antibiotic concentrations were 100 μg/ml carbenicillin, 50 μg/ml kanamycin, or 100 μg/ml hygromycin for *Escherichia coli* and 20 μg/ml kanamycin or 50 μg/ml hygromycin for mycobacteria.

#### Sequence Homology Analysis and Structure Prediction

Amino acid sequences for Sap (Rv3821) and Chp1 (Rv3822) were obtained from TubercuList ([@B25]). Transmembrane helices were predicted by the TMHMM hidden Markov model ([@B52]). The Chp1 sequence was also submitted to the Phyre protein fold recognition server for protein fold and structure prediction ([@B26]).

#### Construction of Gene Disruption Mutants

The Δ*sap* and Δ*chp1* mutant strains were created by homologous recombination using specialized phage transduction ([@B27]). These mutants replaced 429 bp of *sap* (amino acids (aa) 27--171) and 862 bp of *chp1* (aa 44--331) with a hygromycin resistance cassette. Recombinant clones were confirmed by PCR ([supplemental Fig. S7](http://www.jbc.org/cgi/content/full/M111.315473/DC1)). Strains were complemented with integrating plasmids encoding the target gene with a native promoter (upstream 1 kb of the first gene in the putative operon).

#### Lipid Extraction and Mass Spectrometry Analysis

*M. tuberculosis* strains were grown for 3--5 days to late log phase. Cultures were diluted in Tween-free medium to *A*~600~ = 0.25--0.3 and grown for 2 days. Cells were harvested and extracted in 1 ml of hexane/50 ml of culture. The upper organic phase ("surface lipid" fraction) was removed and added to an equal volume of 1:1 chloroform/methanol. The remaining cell pellet and aqueous phase were extracted in 4 ml of 1:1 chloroform/methanol and incubated overnight at room temperature. Cell debris was pelleted by centrifugation, and the supernatant ("cell pellet" fraction) was decanted. All extractions were repeated in at least three independent experiments. The triacylated sulfolipid SL~1868~ was partially purified from wild-type H37Rv cells in an adapted protocol (see [supplemental "Experimental Procedures"](http://www.jbc.org/cgi/content/full/M111.315473/DC1)) ([@B14]).

High-resolution Fourier transform ion cyclotron resonance MS and MS*^n^* data were obtained on an Apex II FT-ICR mass spectrometer (Bruker Daltonics) as described previously ([@B28]) with the following modifications. Two sets of electrospray ionization source tuning parameters were used to acquire mass spectra. For the mass range *m*/*z* 300--1000, the capillary voltage was set to 4.5 kV, the capillary exit voltage was set to −300 V, the skimmer 1 voltage was set to −20 V, and the skimmer 2 voltage was set to −7 V. For the mass range *m*/*z* 1000--3000, the skimmer 2 voltage was lowered to approximately −1 to −3 V.

Additional MS*^n^* spectra were obtained on an LTQ mass spectrometer equipped with an electrospray ionization source (Thermo Finnigan) operating in the negative ion mode. Ions were introduced into the ion source via direct injection at a rate of 5--10 μl/min. Collision-induced dissociation was used for MS*^n^* experiments. The precursor ions were isolated with an isolation width of 1--3 Da, the ions were activated with a 26% normalized collision energy for 100 ms, and the *q~z~* value was maintained at 0.250.

#### Chp1 Subcellular Localization by Fractionation and Immunoblotting

*M. smegmatis* expressing full-length Chp1 with a C-terminal 3×FLAG epitope tag was grown to late log phase (*A*~600~ = 1--1.5) and fractionated by sonication and differential centrifugation to generate cytosol-, membrane-, and cell wall-enriched fractions as described previously ([@B29]) and under [supplemental "Experimental Procedures."](http://www.jbc.org/cgi/content/full/M111.315473/DC1) Protein concentrations were determined by the bicinchoninic acid protein assay, and 5 μg of protein from each fraction were separated by SDS-PAGE. For the anti-MspA blot, samples were extracted with 0.6% octyl thioglucoside as described ([@B30]), and 310 ng of each subcellular fraction were separated by SDS-PAGE. Blots were probed with anti-KatG (Colorado State University), anti-FLAG M2, anti-GroEL2 (Abcam ab20519), and anti-MspA ([@B31]) antibodies and visualized by chemiluminescence.

#### Enzymatic Activity of Chp1-Alkaline Phosphatase and Chp1-β-Galactosidase Fusions

Chp1-alkaline phosphatase (AP) and Chp1-β-gal fusion constructs were electroporated into *M. smegmatis*, and β-gal and AP activities were determined using the substrates 2-nitrophenyl-β-[d]{.smallcaps}-galactopyranoside and 4-nitrophenyl phosphate essentially as reported ([@B35], [@B36]). Activity is reported in Miller units (reaction *A*~420~/(culture *A*~600~ × *V~s~* × min), where *V~s~* = volume of the original culture used in the reaction). Control vectors encoding a secretion signal and secreted AP were a kind gift of Miriam Braunstein (University of North Carolina, Chapel Hill, NC).

#### Expression and Purification of Chp1 Catalytic Domain in E. coli

His-MBP-Chp1-cat, which is the putative catalytic domain of Chp1 fused to an N-terminal His~6~ tag and maltose-binding protein ([@B32]), was expressed in *E. coli* BL21(DE3). Following a 4-h induction with 1 m[m]{.smallcaps} isopropyl β-[d]{.smallcaps}-thiogalactopyranoside at 37 °C, cells were lysed in 50 m[m]{.smallcaps} sodium phosphate (pH 7.2) and 10% glycerol (buffer A). The clarified crude lysate was incubated in batch with 10 ml of amylose resin and washed with 100 ml of buffer A. Bound protein was eluted in buffer A plus 10 m[m]{.smallcaps} maltose, and fractions containing the His-MBP-Chp1-cat fusion protein were pooled, dialyzed, and incubated overnight at 4 °C with tobacco etch virus protease. Cleaved maltose-binding protein and other impurities were removed by incubation with amylose resin. The flow-through fraction containing purified Chp1-cat protein was concentrated and stored at −80 °C.

#### In Vitro Sulfolipid Biosynthetic Reactions

PapA2 and PapA1 were expressed and purified as described ([@B15]). For reconstitution of SL-1 analog biosynthesis, reactions contained 1 μ[m]{.smallcaps} PapA2, 1 μ[m]{.smallcaps} PapA1, 1 μ[m]{.smallcaps} Chp1-cat, 50 μ[m]{.smallcaps} palmitoyl-CoA, and 1 m[m]{.smallcaps} T2S in 100 μl of reaction buffer (100 m[m]{.smallcaps} sodium phosphate (pH 7.2), 1 m[m]{.smallcaps} DTT, and 10% glycerol). To test reactivity with T2S-PS, Chp1-cat was incubated at 1 μ[m]{.smallcaps} with 0.1 m[m]{.smallcaps} T2S-PS in 100 μl of reaction buffer. Competition reactions also included either 0.1 m[m]{.smallcaps} palmitoyl-CoA or 0.1 m[m]{.smallcaps} SL-A. Reactions were incubated at room temperature for 12--16 h. Reactions were extracted with an equal volume of 1:1 chloroform/methanol. The organic phase was co-spotted with an equal volume of 10 mg/ml 2-(4′-hydroxybenzeneazo)benzoic acid suspended in 1:1 water/ethanol. Spots were analyzed by MALDI-TOF-MS in negative ion mode using a 20-kV accelerating voltage and 110-ns extraction delay with 500 shots/spectrum (QB3/Chemistry Mass Spectrometry Facility, University of California at Berkeley). For MS*^n^* analysis (performed as described above), 100 μl of each reaction in 100 m[m]{.smallcaps} ammonium bicarbonate (pH 7.2) were lyophilized and dissolved in methanol prior to analysis.

#### ^35^S and ^14^C Metabolic Labeling and Lipid Analysis by TLC

*M. tuberculosis* strains were grown to late log phase. For ^35^S labeling, cells were resuspended at *A*~600~ ∼ 1 in 10 ml of PBS with 1% acetate and 100 μCi of \[^35^S\]sulfate. For ^14^C labeling, 5 μCi of \[^14^C\]propionic acid were added directly to 10 ml of culture at *A*~600~ ∼ 1. After overnight incubation, cell pellets were extracted sequentially in hexanes and 1:1 chloroform/methanol as described above. An equal volume of extracts resuspended in one-tenth or one-twentieth the original extraction volume was spotted on silica plates (HPTLC Silica Gel 60, EMD Chemicals) and developed in 60:12:1 chloroform/methanol/water, followed by phosphorimaging. For THL treatment experiments, THL in Me~2~SO was added to 10-ml cultures at 0, 10, 20, and 40 μg/ml for 6 h, followed by the addition of 5 μCi of \[^14^C\]propionic acid with further incubation, extraction, and analysis as described above. The lipid phthiocerol dimycocerosate was used as a loading control and resolved in 90:10 petroleum ether/hexanes.

RESULTS AND DISCUSSION
======================

### 

#### Bioinformatic Analysis of Sap and Chp1

The *rv3821* locus encodes a 237-amino acid integral membrane protein homologous to the *M. smegmatis* Gap protein, which is required for glycopeptidolipid transport to the cell surface ([@B33]). Because *rv3821* may be analogously involved in SL-1 transport, we refer to the protein encoded by *rv3821* as Sap ([s]{.ul}ulfolipid-1-[a]{.ul}ddressing [p]{.ul}rotein). Sap has six predicted transmembrane helices, with a hydrophilic domain between helices 3 and 4 (aa 93--134) that is highly variable among identified Gap-like proteins and has been hypothesized to be involved in substrate recognition ([Fig. 2](#F2){ref-type="fig"}) ([@B33]). Sap shares 30% sequence identity with *M. smegmatis* Gap (MSMEG_0403); more distant homologs in *M. tuberculosis* include Rv1517, which is encoded by a locus linked to lipo-oligosaccharide biosynthesis in *Mycobacterium marinum*, and Rv3481c, whose gene is in the same operon as a putative triacylglycerol synthase. Sap also belongs to the LysE protein superfamily (Pfam ID PF01810), whose members have been implicated in small molecule transport in bacteria. For example, LysE from *Corynebacterium glutamicum*, which belongs to the same taxonomic suborder as *M. tuberculosis*, exports [l]{.smallcaps}-lysine and has two homologs in *M. tuberculosis* (Rv0488 and Rv1986) ([@B34]). Other LysE superfamily members are associated with antibiotic resistance and metal ion transport. These analyses support the hypothesis that Gap-like proteins are involved in the export of metabolites across the cell membrane and that Sap specifically may be involved in SL-1 transmembrane transport.

![**Sap and Chp1 are membrane-associated proteins, and Chp1 is related to *M. tuberculosis* CLPs.** *Upper*, a member of the Gap protein family, Sap is an integral membrane protein with six transmembrane helices and a hydrophilic domain (aa 93--134). Chp1 has a single predicted N-terminal transmembrane (*TM*) helix followed by a conserved C-terminal PE-PPE domain with an α/β-hydrolase fold. The domain structures and membrane orientations shown were predicted by the TMHMM algorithm. *Lower*, the Chp1 putative catalytic serine (*black box*) was identified by combined sequence/structure alignment with *P. purpurogenum* acetylxylan esterase II (*AXE II*). In both Chp1 and the related Chp2, the sequence surrounding this serine shares some similarity with the conserved cutinase motif (*boldface* residues). In contrast, the *M. tuberculosis* (*Mtb*) CLPs have an identifiable, albeit modified cutinase motif ([@B38]).](zbc0091297490002){#F2}

The *rv3822* locus encodes a 404-aa protein with a predicted N-terminal transmembrane helix (aa 46--64). The C-terminal domain (aa 104--325) has predicted α/β-hydrolase secondary structure that is conserved among certain members of the *M. tuberculosis* PE and PPE protein families, but the native functions of these proteins are unknown ([@B35], [@B36]). The closest homolog of Rv3822 is Rv1184c, which shares the conserved C-terminal domain and is associated with the polyacyltrehalose biosynthetic locus. Rv3822 is more distantly related to *M. tuberculosis* proteins known as the cutinase-like proteins (CLPs) ([Fig. 2](#F2){ref-type="fig"}), which have been shown to have phospholipase, esterase, and thioesterase activities on a variety of model substrates ([@B37]--[@B39]). One of the CLPs, Rv3802c, is associated with the mycolic acid biosynthetic gene locus and displays hydrolytic activity similar to that of other CLPs, but its possible role in mycolic acid biosynthesis has not been elucidated ([@B37]). Because of its similarity to CLPs, we refer to Rv3822 as a [c]{.ul}utinase-like [h]{.ul}ydrolase [p]{.ul}rotein (Chp1). From an *in silico* structural analysis, we identified a putative catalytic triad (Ser-156--Asp-232--His-255) in Chp1 based on the alignment of these residues with the known active site of a fungal acetylxylan esterase from *Penicillium purpurogenum* ([@B36], [@B40]). On the basis of these analyses, we hypothesized that Chp1 is a membrane-anchored acyltransferase involved in SL-1 biosynthesis.

#### Initial Characterization of Roles of Sap and Chp1 in Mycobacterial Sulfolipid Biosynthesis

To test our hypothesis that Sap and Chp1 function in SL-1 biosynthesis, we compared the lipid profiles of *M. tuberculosis* Erdman wild-type cells and the gene disruption strains Δ*stf0*, Δ*sap*, Δ*chp1*, and Δ*mmpL8*. Cells were grown in the presence of \[^14^C\]propionate, which preferentially labels methyl-branched lipids, and the cell pellet lipid extracts were analyzed by TLC. SL-1 was detected in wild-type cells, but not in Δ*mmpL8* cells ([Fig. 3](#F3){ref-type="fig"}), which accumulated SL~1278~ as observed previously ([@B18], [@B19]). The Δ*chp1* strain displayed a similar phenotype to Δ*mmpL8*. Intriguingly, Δ*sap* not only accumulated SL~1278~ but also produced SL-1, albeit at reduced levels. The complementation of Δ*chp1* and Δ*sap* with their corresponding genes restored the ability of these strains to synthesize SL-1. Thus, the reduced amount of SL-1 produced by the Δ*sap* mutant is not due to a downstream effect of the tagged gene deletion on *chp1* transcription. Metabolic labeling with \[^35^S\]sulfate to detect sulfated lipids yielded analogous results and further confirmed the identity of SL-1 and SL~1278~; neither metabolite was observed in Δ*stf0*, which does not produce sulfated trehalose and therefore lacks sulfated glycolipids (see [supplemental Fig. S1](http://www.jbc.org/cgi/content/full/M111.315473/DC1)) ([@B16]).

![**Chp1 is essential for SL-1 biosynthesis, and Sap modulates SL-1 levels.** *M. tuberculosis* wild-type, Δ*sap*, Δ*chp1*, Δ*mmpL8*, and corresponding complemented strains were metabolically labeled with \[^14^C\]propionate. Cell pellet extracts were analyzed by TLC and phosphorimaging. SL-1 was observed at reduced levels in Δ*sap* and not at all in Δ*chp1* and Δ*mmpL8*, and all three strains accumulated SL~1278~. The wild-type lipid profile was restored by complementation for all strains.](zbc0091297490003){#F3}

These results were corroborated by high-resolution mass spectrometry analysis of the surface lipid and cell pellet lipid fractions, which were obtained by extracting cells with hexanes and 1:1 chloroform/methanol, respectively ([Fig. 4](#F4){ref-type="fig"} and [supplemental Fig. S2](http://www.jbc.org/cgi/content/full/M111.315473/DC1)). Uniquely and unexpectedly, SL~1278~ was found in Δ*chp1* in the surface lipid fraction as well as in the cell pellet fraction. Both this SL~1278~ transport defect and SL-1 biosynthesis were restored by complementation with wild-type *chp1*, confirming that the presence of SL~1278~ in the surface lipid fraction is not due to a nonspecific loss of membrane integrity in Δ*chp1*. The presence of SL~1278~ in the surface lipid fraction in Δ*chp1*, but not in either Δ*sap* or Δ*mmpL8*, suggests that both Sap and MmpL8 are necessary for sulfolipid transport.

![**Δc*hp1* transports SL~1278~ to cell surface.** Electrospray ionization Fourier transform ion cyclotron resonance MS analysis of lipid extracts from *M. tuberculosis* wild-type, Δ*sap*, Δ*chp1*, and Δ*mmpL8* strains showed that the three knock-out strains lack SL-1 and accumulate SL~1278~. (To aid comparison, the *m*/*z* 2460 ion belonging to the SL-1 series is marked with a *plus sign*, and the *m*/*z* 1277.9, 1278.9, and 1279.9 ions belonging to the SL~1278~ series are marked with *asterisks* to distinguish them from other isobaric compounds in the lipid extracts). In addition, SL~1278~ was found in the surface lipid fraction only in Δ*chp1*, and both SL-1 production and the SL~1278~ transport phenotype were restored by complementation with *chp1*.](zbc0091297490004){#F4}

#### Biochemical Characterization of Chp1 Function

To test our hypothesis that Chp1 is membrane-anchored, we determined its subcellular location by fractionating *M. smegmatis* cells expressing full-length Chp1. As predicted, Chp1 was found in the cytosolic membrane- and cell wall-enriched fractions ([Fig. 5](#F5){ref-type="fig"}*a*). On the basis of the hypothesis that Chp1 is most likely associated with the cytosolic membrane, we determined the enzymatic activity of a set of Chp1 fusion constructs attached either to β-gal, which is folded and active only in the cytosol, or to AP, which is active only in the oxidizing environment of the periplasm ([@B36], [@B45]). Fusions of β-gal or AP to the C terminus of full-length Chp1 or the Chp1 putative transmembrane helix (aa 1--71) were expressed in *M. smegmatis*, and the cells were assayed for enzymatic activity. In all cases, activity above background was detected only when Chp1 was fused to β-gal ([Fig. 5](#F5){ref-type="fig"}*b*). Similar results were obtained by qualitative examination of growth on agar containing a chromogenic substrate ([supplemental Fig. S3](http://www.jbc.org/cgi/content/full/M111.315473/DC1)). These data suggest that Chp1 is membrane-associated and oriented with the C-terminal catalytic domain in the cytosol ([Fig. 2](#F2){ref-type="fig"}).

![**Chp1 localizes to cell membrane with catalytic domain in cytosol.** *a*, the immunoblot of subcellular fractions of *M. smegmatis* expressing Chp1 with a C-terminal 3×FLAG tag shows Chp1 enriched in the cell membrane and cell wall. KatG and MspA are markers for the cytosol- and cell wall-enriched fractions. *C*, cytosol; *M*, membrane; *W*, cell wall. *b*, in *M. smegmatis* strains expressing full-length Chp1 or the Chp1 N-terminal (*Nterm*) domain with C-terminal fusions to AP (*gray bars*) and β-gal (*black bars*), enzymatic activity was observed only with β-gal fusions. *M. smegmatis* strains transformed with empty vector or with AP or β-gal with or without an N-terminal secretion signal served as negative and positive controls. Turnover of colorimetric substrates is expressed in Miller units.](zbc0091297490005){#F5}

We next expressed and purified from *E. coli* the conserved C-terminal catalytic domain of Chp1 (Chp1-cat, aa 65--404) and sought to characterize its enzymatic activity in biochemical assays. We first tested for covalent labeling by a fluorescent fluorophosphonate activity-based probe (TAMRA-fluorophosphonate), which selectively modifies the catalytic residue of serine hydrolase superfamily members ([@B41]). Chp1-cat was effectively labeled with TAMRA-fluorophosphonate when properly folded, although not when denatured by heat, and mutation of the putative catalytic Ser-156 to Ala abrogated reactivity, confirming the assignment of Chp1 as a serine hydrolase (see [supplemental "Experimental Procedures" and Fig. S4](http://www.jbc.org/cgi/content/full/M111.315473/DC1)). To test Chp1-cat activity on sulfolipids, we synthesized the diacyl sulfolipid T2S-PS as an SL~1278~ analog. Surprisingly, when Chp1-cat was incubated with T2S-PS, products of lipid acyl transfer were detected in the reaction mixture by MALDI-MS, even in the absence of any acyl-CoA donor ([Fig. 6](#F6){ref-type="fig"}*a*). The higher molecular weight components at *m*/*z* 1192 and 1458 were consistent with one and two additions of stearate to T2S-PS to form T2S-PS~2~ and T2S-PS~3~. These products indicate that Chp1 can use T2S-PS as both an acyl donor and acceptor. The observed products imply that Chp1 catalyzes the regiospecific transfer of a fatty acyl group (in this case, stearate) from the 3′-position of a donor molecule to the 6- or 6′-position of an acceptor molecule. By this mechanism, T2S-P (*i.e.* the monoacylated SL-1 precursor SL~659~) should be generated as a by-product, and indeed, this species is also observed in the mass spectrum. Palmitoyl-CoA did not successfully compete with T2S-PS as an acyl donor, as the products of palmitate addition to T2S-PS were not detected ([supplemental Fig. S5*A*](http://www.jbc.org/cgi/content/full/M111.315473/DC1)). Chp1-cat also did not appear to use SL-A, a tetraacylated analog of SL-1, as an acyl donor to T2S-PS but was capable of hydrolyzing SL-A ([supplemental Fig. S5, *B* and *C*](http://www.jbc.org/cgi/content/full/M111.315473/DC1)) ([@B24]).

![**Chp1 uses diacyl-T2S as acyl donor and acceptor.** *a*, MALDI-MS analysis revealed higher molecular weight reaction products when Chp1-cat was incubated with T2S-PS. The observed ions at *m*/*z* 659.1, 1192.4, and 1458.4 are consistent with the formation of the designated sulfolipid species. Ions labeled with *asterisks* indicate a minor T2S-P~2~ contaminant in the T2S-PS stock, as well as the corresponding T2S-P~2~S and T2S-PS~2~ product ions following stearate addition from T2S-PS. *b*, reaction scheme for Chp1 activity on T2S-PS. *c*, MS^2^ and subsequent MS^3^ (*inset*) analysis of the *m*/*z* 1192 ion showing fragmentation peaks consistent with stearate on either the glucose or acylsulfoglucose monomers (6- and 6′-positions of T2S, respectively). *d*, incubation of PapA2, PapA1, and Chp1 with T2S and palmitoyl-CoA yields ions at *m*/*z* 897.4, 1135.4, and 1374.4, consistent with the indicated acylation products.](zbc0091297490006){#F6}

Tandem MS (MS*^n^*) fragmentation of the T2S-PS~3~ ion at *m*/*z* 1192 revealed a mixture of regioisomers in which the additional stearoyl group was attached to either glucose monomer of T2S ([Fig. 6](#F6){ref-type="fig"}*b*). SL~1868~, a triacylated T2S species (trehalose-2-sulfate-3′-palmitate-4′,6′-bisphthioceranoate) purified from wild-type H37Rv *M. tuberculosis*, was found by MS*^n^* analysis to comprise an analogous mixture of regioisomers ([supplemental Fig. S6](http://www.jbc.org/cgi/content/full/M111.315473/DC1)). On the basis of these data, we postulate that Chp1 catalyzes acyl transfer to either glucose monomer of the acceptor molecule and that this lack of regioselectivity with respect to the acceptor substrate is physiologically relevant.

Finally, we reconstituted the biosynthesis of SL-1 in a one-pot reaction by combining the acyltransferases PapA2 and PapA1 and Chp1-cat with palmitoyl-CoA as the acyl donor and T2S as the acceptor substrate. The product mixture included all of the products expected from a series of acyl transfer reactions, including the mono-, di-, tri-, and tetraacylated species ([Fig. 6](#F6){ref-type="fig"}*d*). In the absence of Chp1, only the mono- and diacylated species were detected, as observed previously ([@B15]).

#### Chp1 Inhibition by THL in M. tuberculosis

Because Chp1 is a serine hydrolase-type enzyme that recognizes a hydrophobic substrate, we hypothesized that it may be inhibited by THL, a clinically approved lipase inhibitor. More commonly known as Orlistat (Xenical, Roche Applied Science), THL is a lipophilic lactone active against gastric lipase and is approved for the treatment of obesity. THL has been shown to have bactericidal effects on some mycobacterial species. More specifically, THL inhibits general triacylglycerol lipase activity in *Mycobacterium bovis* bacillus Calmette-Guérin as well as the *in vitro* activity of the CLP family member Rv3802c and the extracellular lipase Rv0183 ([@B37], [@B42]--[@B45]). In this study, *M. tuberculosis* treated with THL and labeled with \[^14^C\]propionate showed a dose-dependent decrease in SL-1 production with a concomitant accumulation of SL~1278~ ([Fig. 7](#F7){ref-type="fig"}). SL-1 synthesis was not completely suppressed even at THL concentrations close to the minimum inhibitory concentration of 50 μg/ml, consistent with the hypothesis that THL has multiple targets that contribute to its bactericidal activity. These results support our prediction that the lipophilic lactone THL preferentially inhibits Chp1 over the SL-1 acyltransferases PapA1 and PapA2 due to its higher affinity for Chp1 and/or its preferential partitioning into lipid membranes where Chp1 resides.

![**THL treatment specifically inhibits conversion of SL~1278~ to SL-1.** *Upper panel*, lipid extracts from *M. tuberculosis* treated with different concentrations of THL for 6 h followed by \[^14^C\]propionate labeling reveal the dose-dependent but incomplete inhibition of SL-1 formation and the accumulation of SL~1278~ by TLC and phosphorimaging. *Lower panel*, phthiocerol dimycocerosate (*PDIM*) loading control.](zbc0091297490007){#F7}

#### Conclusions

Based on the *in vitro* data presented here, the SL-1 biosynthetic pathway appears complete: Stf0 sulfates trehalose to generate T2S, which is then acylated once by PapA2, once by PapA1 using fatty acids from Pks2, and twice by Chp1. However, the lipid profiles of the Δ*mmpL8* and Δ*sap* mutants contradict this linear scheme. Following formation of the SL~1278~ precursor, SL-1 biosynthesis in *M. tuberculosis* is also dependent on the transport-associated membrane protein MmpL8 and Sap (Rv3821). Indeed, although Δ*mmpL8*, Δ*sap*, and Δ*chp1* all accumulate SL~1278~, only in Δ*chp1* is SL~1278~ detected in the surface lipid fraction, implying that MmpL8 and Sap together mediate sulfolipid transport. However, whereas MmpL8 is essential for SL-1 formation, Sap appears to modulate flux through the pathway, similar to MmpS4-mediated modulation of glycopeptidolipid levels in *M. smegmatis* ([@B46]).

The accumulation of SL~1278~ in Δ*mmpL8* and Δ*sap* is consistent with two models for the coupling of biosynthesis and transport ([Fig. 8](#F8){ref-type="fig"}) ([@B13], [@B14]). In the "sequential" model, MmpL8 transports SL~1278~, which is then processed to SL-1 in the periplasm. (We here assume that MmpL8 acts solely as a lipid flippase; the question of how SL-1 is transported from the periplasm to its ultimate location in the mycobacterial outer membrane will not be discussed further.) However, this model contradicts our Chp1 topology results and also requires retrograde transport of SL~659~ by-products for re-entry into the SL-1 pathway ([Fig. 8](#F8){ref-type="fig"}).

![**Proposed model for SL-1 biosynthesis and transmembrane transport.** The data are most consistent with a model in which Chp1 completes SL-1 biosynthesis in the cytosolic leaflet, and MmpL8 and Sap transport SL-1 across the membrane. The membrane localization of Chp1 and the coupling of biosynthesis and transport via MmpL8 suggest that the SL-1 machinery may form a macromolecular complex to facilitate function. The mechanisms by which SL-1 is transported to the mycobacterial outer membrane are unknown. (Note that, in this figure, the hydroxyphthioceranoic groups on SL-1 are truncated.)](zbc0091297490008){#F8}

The data presented here and elsewhere more strongly support the "scaffolding" model, in which MmpL8 facilitates biosynthesis and then transports the final SL-1 product across the cytosolic membrane. MmpL8 could couple lipid biosynthesis and transport by acting as a scaffold that nucleates a macromolecular complex of cytosolic PapA1, PapA2, Pks2, and membrane-associated Chp1. The scaffold concept has a precedent in the *M. tuberculosis* phthiocerol dimycocerosate lipid biosynthetic pathway, in which the transporter MmpL7 and the biosynthetic enzyme PpsE were shown to interact in a yeast two-hybrid assay ([@B47]). In the SL-1 pathway, the close association of related enzymes could facilitate recycling of the Chp1 side product SL~659~ back into the biosynthetic pathway and thereby drive the Chp1 reaction forward. Importantly, a recent high-resolution structural analysis of lipids extracted from Δ*mmpL8* revealed unexpected triacylated sulfolipids, suggesting that Chp1 is active in the absence of MmpL8, although at reduced levels ([@B48]).

Sap could be an additional component of the proposed scaffold. Although Sap is not absolutely essential for SL-1 biosynthesis, it appears to potentiate SL-1 levels and may confer specificity for sulfolipids over structurally similar glycolipids such as trehalose monomycolate and polyacyltrehalose. In this role, Sap may be functionally analogous to small integral membrane proteins that are substrate-specific components in bacterial vitamin transport ([@B49]). Close association between membrane-associated Chp1 and an MmpL8-Sap complex could aid transport of SL-1 away from Chp1. This action would prevent reverse hydrolysis, a Chp1 activity detected at low levels *in vitro* ([supplemental Fig. S5*C*](http://www.jbc.org/cgi/content/full/M111.315473/DC1)).

Chp1 catalysis of two successive acyl transfers is similar to the activity of the polyacyltrehalose enzyme PapA3, which esterifies trehalose with palmitic and mycolipenic acids ([@B50]). However, unlike the PapA enzymes, Chp1 does not use an activated thioester donor such as an acyl-CoA but rather catalyzes regioselective transesterification between two substrate molecules. This mechanism has precedent in *M. tuberculosis* with the antigen 85 complex (Ag85A, Ag85B, and Ag85C), a group of cell wall mycolyltransferases that synthesize trehalose dimycolate from two molecules of trehalose monomycolate ([@B51]). In comparison, the activity of Chp1 is more complex, with a combination of specificity and promiscuity that raises intriguing questions about how it achieves substrate recognition and chemical specificity. On the one hand, Chp1 is selective for diacyl over monoacyl sulfolipids and specific for the donor 3′-T2S position, yet it can accommodate two different triacyl regioisomers and catalyze ester formation at two chemically nonequivalent positions. As has been noted previously, the SL-1 and polyacyltrehalose biosynthetic loci are structurally similar ([@B50]). Indeed, the closest homolog of Chp1 is Chp2, encoded by *rv1184c* in the polyacyltrehalose locus (43% sequence identity), and preliminary results indicate that Chp2 is also essential for polyacyltrehalose biosynthesis.[^7^](#FN8){ref-type="fn"}

These data thus define a class of mechanistically similar glycolipid acyltransferases that comprise the Ag85 complex, Chp1, and possibly Chp2. Other members may include eight *M. tuberculosis* PE/PPE proteins that are the closest homologs of Chp1 and Chp2 ([@B35]). Although the PE/PPE protein family constitutes ∼10% of the *M. tuberculosis* genome, only Rv3097c (PE_PGRS63; LipY) has assigned enzymatic activity as a cell wall-associated triacylglycerol lipase ([@B53]). Whether our new insights into Chp1 acyltransferase activity will aid the functional assignment of these conserved proteins and whether they can be targeted as a group by inhibitory molecules such as THL await further investigation.
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